Artemis Women's Health Foundation

🌟 Gameto has announced the world’s first live birth using Fertilo, a new technology that matures eggs outside the body. The birth, which took place at Clinica Santa Isabel in Lima, Peru, represents a significant advancement in fertility treatment by eliminating approximately 80% of hormone injections typically required in conventional IVF. The technology uses engineered ovarian support cells to recreate the natural egg maturation process in a laboratory setting, reducing treatment cycles from the traditional 10-14 days to just three days. 🤱 💬 “We are delighted to celebrate the world’s first live birth conceived using Fertilo. By overcoming the major challenges of conventional IVF, such as long treatment cycles, significant side effects, and the emotional and physical strain, Fertilo provides a potentially faster, safer, and more accessible solution for families. This milestone marks a turning point in reproductive health and highlights the first application of iPSC technology in IVF and the immense potential of our technology.” Dina Radenkovic Turner, CEO & co-founder of Gameto #femtech #womenshealth #womenshealthinnovation #health #healthcare #fertility #reproductivehealth #ivf #milestone #biotech #startup #scaleup #research #clinicalresearch #science

On December 9th, we took part in the 𝗧𝗲𝗰𝗵𝟰𝗘𝘃𝗮 conference in Lausanne, which had a strong focus on maternal health. Speakers like Antoniya Georgieva and Pascal Koenig described how technology can make pregnancies and deliveries safer around the world. And during the showcases, startups like Galena Innovations and Fetosense® by CareNX pitched their maternal health innovations. Thanks to the organizing team at Tech4Eva and their partners for a great event, and congratulations to the participating entrepreneurs!  👏🏼 ➡️ If you are working on an innovative Femtech solution, you, too, can apply to Tech4Eva's 6-month virtual accelerator program for 2025! ➡️ Applications can be submitted until February 15, 2025 at: https://www.tech4eva.ch/ #femtech #womenshealth #startups #innovation Lidia Zabala, Simone Theiss, Lan Zuo Gillet hormona, CareNX Innovations cc Diagnostics, Calico Biosystems, Babyndex, Herosupport SA, EndoCure Ltd., VivoSensMedical GmbH, Mamotest, DeepLook Medical, Harmonia Healthcare, Vital Start Health, Cosm Medical, Namida Lab, Inc., Sin Reglas, Galena Innovations

How can we move from 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝗮𝘁𝗶𝗰 𝘁𝗼 𝗱𝗶𝘀𝗲𝗮𝘀𝗲-𝗺𝗼𝗱𝗶𝗳𝘆𝗶𝗻𝗴 therapies in 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗼𝘀𝗶𝘀? The journey 𝗳𝗿𝗼𝗺 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝗮𝘁𝗶𝗰 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝘁𝗼 𝗱𝗶𝘀𝗲𝗮𝘀𝗲-𝗺𝗼𝗱𝗶𝗳𝘆𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 has revolutionized patient care across multiple therapeutic areas: ➡️ In 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆, while many drugs are not strictly disease-modifying, the evolution of 𝗲𝗻𝗱𝗽𝗼𝗶𝗻𝘁𝘀, 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗽𝗮𝗿𝗮𝗱𝗶𝗴𝗺𝘀, better 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 tools, and the use of 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 over the past two decades has significantly improved patient outcomes. ➡️ Similarly, in 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀, 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀, 𝗮𝗻𝗱 𝗲𝗻𝗱𝗽𝗼𝗶𝗻𝘁𝘀 have evolved with the introduction of targeted biologics. 𝗘𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗼𝘀𝗶𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝘀 𝗮 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝗯𝗹𝗲 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗳𝗼𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. In endometriosis, current research is uncovering new mechanisms of action that could redefine treatment paradigms. These approaches mirror the success seen in rheumatoid arthritis and the targeted approach in oncology, where understanding the molecular basis of diseases has led to breakthrough therapies. Pharma and diagnostic companies, and researchers are encouraged to explore these novel mechanisms of action, as endometriosis offers a significant unmet medical need and a substantial commercial opportunity. By investing in potential disease-modifying therapies for endometriosis, companies can lead the charge in transforming women’s health care, much like the advancements seen in rheumatoid arthritis and oncology. Ready to learn more? 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐨𝐮𝐫 𝐖𝐡𝐢𝐭𝐞 𝐏𝐚𝐩𝐞𝐫 𝐧𝐨𝐰:  https://lnkd.in/e3aNdA4x #ArtemisWomensHealthFoundation #Endometriosis #WomensHealth #MedicalInnovation #NonHormonalTreatments #Adenomyosis #Innovation #Healthcare #DownloadNow #Inflammation #Fibrosis #Angiogenesis #PrecisionMedicine

What if endometriotic lesions could be removed with novel medicines instead of surgery? What if new imaging methods could replace laporoscopic surgery for the definitive diagnosis of endometriosis? What if biomarkers could diagnose endometriosis early? Did you know endometriosis affects over 10% of women during their reproductive years, significantly impacting their quality of life? Our new White Paper explores the critical need for non-hormonal treatment options for endometriosis and adenomyosis. Despite the high prevalence, new therapies are lacking, with current treatments being either hormonal or invasive, representing a high cost to patients and society. The Artemis Women's Health Foundation and Catenion  have created a comprehensive guide for startups, investors and pharma companies who want to change the status quo and bring innovative treatments to Endometriosis and Adenomyosis patients. Ready to learn more? Download our White Paper now: https://lnkd.in/e3aNdA4x  #ArtemisWomensHealthFoundation #Endometriosis #WomensHealth #MedicalInnovation #NonHormonalTreatments #Adenomyosis #Innovation #Healthcare #DownloadNow Gesynta Pharma AB, Maipl Therapeutics, Inc. FimmCyte, Serac Healthcare, Hera Biotech Xena Dx (Techstars '23) Heranova Lifesciences Scanvio Medical MiMARK Diagnostics DotLab curE-me, Fiftyone Bio

𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗘𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗼𝘀𝗶𝘀 & 𝗔𝗱𝗲𝗻𝗼𝗺𝘆𝗼𝘀𝗶𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁:  𝗙𝗿𝗼𝗺 𝗡𝗼𝘃𝗲𝗹 𝗧𝗮𝗿𝗴𝗲𝘁𝘀 𝘁𝗼 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 What’s the key to unlocking new therapies for these high-unmet-need conditions? Dive into our latest insights: 1. Explore highlights in our LinkedIn article below 2: Access our comprehensive white paper for in-depth analysis https://lnkd.in/ds9GW5s2 𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀: What do you think is the biggest obstacle to bringing new treatments to patients? We’re eager to hear your perspective in the comments! #Endometriosis #Adenomyosis #Drugdevelopment #WomensHealth #ArtemisWomensHealthFoundation

Want to optimize your company’s partnering strategy? Learn how successful licensing deals and powerful alliances drive innovation in Women’s Health. ► 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 for the webinar on "𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗶𝗻 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵", co-organized by Artemis and Locust Walk. https://lnkd.in/eiCHMigi Decision makers from pharma companies 𝗙𝗲𝗿𝗿𝗶𝗻𝗴 and 𝗣𝗶𝗲𝗿𝗿𝗲 𝗙𝗮𝗯𝗿𝗲 will discuss their processes and priorities, while a Managing Director from the investment bank 𝗟𝗼𝗰𝘂𝘀𝘁 𝗪𝗮𝗹𝗸 shares the "do's and don'ts" of partnering in today's environment. This event is brought to you by: - Artemis Women's Health Foundation, a non-profit organization fostering healthcare innovation for women worldwide, and - Locust Walk, a global investment bank supporting innovative life science companies in corporate development and capital raising Andy Meyerson - Locust Walk Casper Johansen - Ferring Pharmaceuticals Claire Kanony-Truc - Pierre Fabre Laboratories Liliane Brunner Halbach - Artemis Women's Health Foundation #womenshealth #startups #innovation #biotech #biopharma #pharmaceuticals #venturecapital #partnering #businessdevelopment #strategy

Please share your thoughts, ahead of the "BD in WH" webinar on Nov 13th:

This webinar, co-organized by Artemis and Locust Walk, focuses on "𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗶𝗻 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵": - learn how to 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲 your firm's partnering strategy - hear how you can 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻 your company as the ideal partner - find out how dealmakers 𝗰𝗿𝗲𝗮𝘁𝗲 successful alliances ► 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/d967JYA9 Decision makers from pharma companies 𝗙𝗲𝗿𝗿𝗶𝗻𝗴 and 𝗣𝗶𝗲𝗿𝗿𝗲 𝗙𝗮𝗯𝗿𝗲 will discuss their processes and priorities, while a Managing Director from the investment bank 𝗟𝗼𝗰𝘂𝘀𝘁 𝗪𝗮𝗹𝗸 shares the "do's and don'ts" of partnering in today's environment. This event is brought to you by: - Artemis Women's Health Foundation, a non-profit organization fostering healthcare innovation for women worldwide, and - Locust Walk, a global investment bank supporting innovative life science companies in corporate development and capital raising Andy Meyerson - Locust Walk Casper Johansen - Ferring Pharmaceuticals Claire Kanony-Truc - Pierre Fabre Laboratories Liliane Brunner Halbach - Artemis Women's Health Foundation #womenshealth #startups #innovation #biotech #biopharma #pharmaceuticals #venturecapital #partnering #businessdevelopment #strategy

Tic-toc! The Tech4Eva Roadshow - Supporting Women's Health in the Workplace is coming soon! 👩🔧👩⚕️👷♀️👩💻👩💼 Did you know that companies that offer comprehensive support for women’s health have higher productivity, better retention of female employees and help improve health outcome for women? 🚀 In partnership with SICPA, we're excited to announce that the 2024 Tech4Eva Roadshow is just around the corner! Companies that support women’s health see boosts in productivity, employee retention, and overall well-being. Discover how employers can step up by offering key benefits such as breastfeeding breaks, mental health support, and much more! 💡 Stay tuned for insights into how SICPA’s ecosystem is fostering innovation in women's health. Get ready to meet the Tech4Eva start-ups making an impact. - Cosm Medical - hormona - Vital Start Health - VivoSensMedical GmbH - Babyndex - Fetosense® by CareNX - Galena Innovations] - Harmonia Healthcare] - Mamotest] - EndoCure Ltd. - CC Diagnostics] - Calico Biosystems - Herosupport SA - DeepLook Medical - Namida Lab, Inc. - Sin Reglas Confirmed Speakers to date: Lan Zuo Gillet of EPFL Innovation Park, Amal Rabbani of SICPA, Sapna Rao of Philips, Hanne Langmoen of embecta, Cindy Johanna Rodriguez Avila, MBA of Procter & Gamble, Monika Zielonka of Women in Tech® Switzerland, and Iuliana Volery, Talent Acquisition & Employer Branding Manager, SICPA Don't miss out and be part of the movement to empower women in the workplace! 🔗Register now: https://hubs.li/Q02TB9tH0 EPFL Innovation Park, Groupe Mutuel #Femtech #medtech #womenshealthmatters #WomensHealth #Innovation #Healthtech #Startups

➡️ Read 5 key learnings from our interview with two Women's Health CEOs ➡️ Register for our upcoming webinar on "Bus Dev in Women's Health"